EJNMMI研究在核醫(yī)學(xué)和分子成像領(lǐng)域發(fā)表了新的基礎(chǔ)、轉(zhuǎn)化和臨床研究。常規(guī)功能包括原創(chuàng)研究文章，快速交流創(chuàng)新研究的初步數(shù)據(jù)，有趣的案例報(bào)告，社論，以及給編輯的信件。也歡迎有關(guān)基礎(chǔ)科學(xué)、基礎(chǔ)方面的教育文章，以及與臨床前研究和臨床研究或倫理方面的研究有關(guān)的爭議。及時(shí)的綜述提供了核醫(yī)學(xué)和分子成像技術(shù)的當(dāng)前應(yīng)用、成像研究中的問題和轉(zhuǎn)化方面的最新進(jìn)展。主要重點(diǎn)放在在分子探針的更廣泛背景下發(fā)展放射性藥物的靶向成像，以增進(jìn)對(duì)潛在疾病的復(fù)雜生物學(xué)過程的了解和特征描述，并開發(fā)、測(cè)試和指導(dǎo)包括放射性核素治療在內(nèi)的新治療模式。

EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.